top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

13/02/2026













HanchorBio's HCB101 received the FDA orphan drug designation for gastric cancer (Ref)


The US FDA granted the Orphan Drug Designation to HanchorBio's HCB101 (CD47–SIRPα pathway inhibitor) for the treatment of gastric cancer.


  • The designation covers gastric cancer broadly, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative subtypes


  • HCB101 is currently being evaluated in multiple ongoing clinical studies, including a Phase 1b/2a trial (NCT06771622) assessing HCB101 in combination with ramucirumab and paclitaxel in second-line advanced gastric cancer

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page